TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:TNGX

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/23	22 : 18	PR Newswire (US)	Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/23	20 : 18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/23	20 : 00	Business Wire	Tango Therapeutics Announces Discontinuation of TNG348 Program	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/08	20 : 21	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/08	20 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TNGX	Tango Therapeutics Inc
2024/05/08	20 : 00	Business Wire	Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights	NASDAQ:TNGX	Tango Therapeutics Inc
2024/04/02	05 : 48	Business Wire	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:TNGX	Tango Therapeutics Inc
2024/03/18	20 : 00	Business Wire	Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights	NASDAQ:TNGX	Tango Therapeutics Inc
2024/03/06	21 : 00	Business Wire	Tango Therapeutics to Participate in Upcoming Investor Conferences	NASDAQ:TNGX	Tango Therapeutics Inc
2024/03/06	06 : 47	GlobeNewswire Inc.	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/09	11 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/09	11 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/07	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/06	06 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/02/06	06 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2024/01/31	21 : 00	GlobeNewswire Inc.	Tango Therapeutics to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	NASDAQ:TNGX	Tango Therapeutics Inc
2024/01/06	06 : 05	GlobeNewswire Inc.	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:TNGX	Tango Therapeutics Inc
2024/01/04	16 : 47	PR Newswire (US)	Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	NASDAQ:TNGX	Tango Therapeutics Inc
2024/01/03	21 : 00	GlobeNewswire Inc.	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/13	21 : 00	GlobeNewswire Inc.	Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/08	21 : 29	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/08	21 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/08	21 : 00	GlobeNewswire Inc.	Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/07	21 : 00	GlobeNewswire Inc.	Tango Therapeutics to Present at the Jefferies London Healthcare Conference	NASDAQ:TNGX	Tango Therapeutics Inc
2023/11/03	05 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TNGX	Tango Therapeutics Inc
2023/10/19	06 : 23	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:TNGX	Tango Therapeutics Inc
2023/09/18	20 : 00	GlobeNewswire Inc.	Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	NASDAQ:TNGX	Tango Therapeutics Inc
2023/09/12	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:TNGX	Tango Therapeutics Inc
2023/09/06	20 : 00	GlobeNewswire Inc.	Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers	NASDAQ:TNGX	Tango Therapeutics Inc
2023/09/05	20 : 00	GlobeNewswire Inc.	Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:TNGX	Tango Therapeutics Inc